S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.27 (+1.53%)
AMD   117.86 (-1.35%)
T   15.21 (-3.80%)
F   12.39 (+2.31%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.17%)
GE   105.80 (+1.08%)
DIS   90.77 (+2.46%)
AMC   4.55 (+0.00%)
PFE   38.36 (+0.89%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.27 (+1.53%)
AMD   117.86 (-1.35%)
T   15.21 (-3.80%)
F   12.39 (+2.31%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.17%)
GE   105.80 (+1.08%)
DIS   90.77 (+2.46%)
AMC   4.55 (+0.00%)
PFE   38.36 (+0.89%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.27 (+1.53%)
AMD   117.86 (-1.35%)
T   15.21 (-3.80%)
F   12.39 (+2.31%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.17%)
GE   105.80 (+1.08%)
DIS   90.77 (+2.46%)
AMC   4.55 (+0.00%)
PFE   38.36 (+0.89%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.27 (+1.53%)
AMD   117.86 (-1.35%)
T   15.21 (-3.80%)
F   12.39 (+2.31%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.17%)
GE   105.80 (+1.08%)
DIS   90.77 (+2.46%)
AMC   4.55 (+0.00%)
PFE   38.36 (+0.89%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News

$1.03
-0.06 (-5.50%)
(As of 05:11 PM ET)
Compare
Today's Range
$1.03
$1.14
50-Day Range
$0.60
$1.11
52-Week Range
$0.55
$7.60
Volume
33,520 shs
Average Volume
194,367 shs
Market Capitalization
$11.25 million
P/E Ratio
0.15
Dividend Yield
N/A
Price Target
N/A

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
7.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.58mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.67) to ($2.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

436th out of 983 stocks

Pharmaceutical Preparations Industry

210th out of 486 stocks


ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Acelrx (ACRX) Receives a Hold from H.C. Wainwright
See More Headlines

ACRX Price History

ACRX Company Calendar

Last Earnings
3/30/2023
Today
6/02/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
43
Year Founded
N/A

Profitability

Net Income
$47.76 million
Net Margins
2,696.50%
Pretax Margin
3,946.35%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$1.30 per share

Miscellaneous

Free Float
10,312,000
Market Cap
$11.90 million
Optionable
Optionable
Beta
0.25

Key Executives

  • Vincent J. Angotti
    President, Chief Executive Officer & Director
  • Raffi Asadorian
    Chief Financial & Accounting Officer
  • Pamela Pierce Palmer
    Director & Chief Medical Officer
  • Badri N. Dasu
    Chief Engineering Officer
  • Mark A. Evashenk
    Vice President-Clinical Operations













ACRX Stock - Frequently Asked Questions

How have ACRX shares performed in 2023?

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 51.8% and is now trading at $1.09.
View the best growth stocks for 2023 here
.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 765,800 shares, a drop of 10.5% from the April 30th total of 855,800 shares. Based on an average trading volume of 204,900 shares, the days-to-cover ratio is currently 3.7 days. Approximately 7.1% of the company's shares are sold short.
View AcelRx Pharmaceuticals' Short Interest
.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACRX earnings forecast
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings data on Thursday, March, 30th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.90. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 93.99%.

When did AcelRx Pharmaceuticals' stock split?

AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian Adams and Vincent J Angotti.
View institutional ownership trends
.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.09.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $11.90 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or $6.91 on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -